BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen QY, Chen YX, Han QY, Zhang JG, Zhou WJ, Zhang X, Ye YH, Yan WH, Lin A. Prognostic Significance of Immune Checkpoints HLA-G/ILT-2/4 and PD-L1 in Colorectal Cancer. Front Immunol 2021;12:679090. [PMID: 34054869 DOI: 10.3389/fimmu.2021.679090] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Yang Y, Wang W, Weng J, Li H, Ma Y, Liu L, Ma W. Advances in the study of HLA class Ib in maternal-fetal immune tolerance. Front Immunol 2022;13:976289. [DOI: 10.3389/fimmu.2022.976289] [Reference Citation Analysis]
2 Yu S, Li X, Ma M, Yang R, Zhang J, Wu S. The Immunological Contribution of a Novel Metabolism-Related Signature to the Prognosis and Anti-Tumor Immunity in Cervical Cancer. Cancers 2022;14:2399. [DOI: 10.3390/cancers14102399] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Subbarayan K, Massa C, Leisz S, Steven A, Bethmann D, Biehl K, Wickenhauser C, Seliger B. Biglycan as a potential regulator of tumorgenicity and immunogenicity in K-RAS-transformed cells. Oncoimmunology 2022;11:2069214. [PMID: 35529675 DOI: 10.1080/2162402X.2022.2069214] [Reference Citation Analysis]
4 Morandi F, Airoldi I. HLA-G and Other Immune Checkpoint Molecules as Targets for Novel Combined Immunotherapies. Int J Mol Sci 2022;23:2925. [PMID: 35328349 DOI: 10.3390/ijms23062925] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Rashidi S, Vieira C, Tuteja R, Mansouri R, Ali-hassanzadeh M, Muro A, Nguewa P, Manzano-román R. Immunomodulatory Potential of Non-Classical HLA-G in Infections including COVID-19 and Parasitic Diseases. Biomolecules 2022;12:257. [DOI: 10.3390/biom12020257] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Zheng Z, Bian C, Wang H, Su J, Meng L, Xin Y, Jiang X. Prediction of immunotherapy efficacy and immunomodulatory role of hypoxia in colorectal cancer. Ther Adv Med Oncol 2022;14:175883592211383. [DOI: 10.1177/17588359221138383] [Reference Citation Analysis]
7 Li P, Wang N, Zhang Y, Wang C, Du L. HLA-G/sHLA-G and HLA-G-Bearing Extracellular Vesicles in Cancers: Potential Role as Biomarkers. Front Immunol 2021;12:791535. [PMID: 34868081 DOI: 10.3389/fimmu.2021.791535] [Reference Citation Analysis]
8 Vuletić A, Mirjačić Martinović K, Tišma Miletić N, Zoidakis J, Castellvi-Bel S, Čavić M. Cross-Talk Between Tumor Cells Undergoing Epithelial to Mesenchymal Transition and Natural Killer Cells in Tumor Microenvironment in Colorectal Cancer. Front Cell Dev Biol 2021;9:750022. [PMID: 34858978 DOI: 10.3389/fcell.2021.750022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
9 Lin A, Yan WH. HLA-G/ILTs Targeted Solid Cancer Immunotherapy: Opportunities and Challenges. Front Immunol 2021;12:698677. [PMID: 34276691 DOI: 10.3389/fimmu.2021.698677] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]